Both germline-mutated and Cluster 1 MBC cases were characterized by a high HER2 score, suggesting that the HER2 pathway may be active; thus, they might benefit from treatment with trastuzumab, as previously reported in female BC [36,37]. Here, ERBB2 is linked to breast cancer.